ERBB2 and breast cancer: The phase II randomized HER2CLIMB trial enrolled patients with HER2-positive advanced BC previously treated with trastuzumab, pertuzumab, and T-DM1 to receive tucatinib or placebo, in combination with trastuzumab and capecitabine.